Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Lung Cancer

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 42 articles:
HTML format



Single Articles


    August 2020
  1. BRASTIANOS PK, Lee EQ, Cohen JV, Tolaney SM, et al
    Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
    Nat Med. 2020;26:1280-1284.
    PubMed     Abstract available


    July 2020
  2. ABDULJABBAR K, Raza SEA, Rosenthal R, Jamal-Hanjani M, et al
    Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
    Nat Med. 2020;26:1054-1062.
    PubMed     Abstract available


    June 2020
  3. LU Y, Xue J, Deng T, Zhou X, et al
    Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
    Nat Med. 2020 Jun 18. pii: 10.1038/s41591-020-0973.
    PubMed     Abstract available


  4. BISWAS D, Birkbak NJ, Rosenthal R, Hiley CT, et al
    Publisher Correction: A clonal expression biomarker associates with lung cancer mortality.
    Nat Med. 2020 Jun 3. pii: 10.1038/s41591-020-0899.
    PubMed     Abstract available


  5. JOSHI K, de Massy MR, Ismail M, Reading JL, et al
    Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
    Nat Med. 2020 Jun 3. pii: 10.1038/s41591-020-0866.
    PubMed     Abstract available


  6. BOCKORNY B, Semenisty V, Macarulla T, Borazanci E, et al
    BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
    Nat Med. 2020;26:878-885.
    PubMed     Abstract available


    April 2020
  7. LU Y, Xue J, Deng T, Zhou X, et al
    Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
    Nat Med. 2020 Apr 27. pii: 10.1038/s41591-020-0840.
    PubMed     Abstract available


    February 2020
  8. LAUGHNEY AM, Hu J, Campbell NR, Bakhoum SF, et al
    Regenerative lineages and immune-mediated pruning in lung cancer metastasis.
    Nat Med. 2020;26:259-269.
    PubMed     Abstract available


  9. HATA AN, Shaw AT
    Resistance looms for KRAS(G12C) inhibitors.
    Nat Med. 2020;26:169-170.
    PubMed    


    January 2020
  10. DRILON A, Clark JW, Weiss J, Ou SI, et al
    Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
    Nat Med. 2020;26:47-51.
    PubMed     Abstract available


    November 2019
  11. CHOWELL D, Krishna C, Pierini F, Makarov V, et al
    Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.
    Nat Med. 2019;25:1715-1720.
    PubMed     Abstract available


  12. KIM JW, Marquez CP, Kostyrko K, Koehne AL, et al
    Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
    Nat Med. 2019;25:1783-1795.
    PubMed     Abstract available


    October 2019
  13. BISWAS D, Birkbak NJ, Rosenthal R, Hiley CT, et al
    A clonal expression biomarker associates with lung cancer mortality.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0595.
    PubMed     Abstract available


  14. JOSHI K, Robert de Massy M, Ismail M, Reading JL, et al
    Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
    Nat Med. 2019 Oct 4. pii: 10.1038/s41591-019-0592.
    PubMed     Abstract available


  15. GANESH K, Wu C, O'Rourke KP, Szeglin BC, et al
    A rectal cancer organoid platform to study individual responses to chemoradiation.
    Nat Med. 2019;25:1607-1614.
    PubMed     Abstract available


  16. CHEMI F, Rothwell DG, McGranahan N, Gulati S, et al
    Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.
    Nat Med. 2019;25:1534-1539.
    PubMed     Abstract available


  17. COURTIOL P, Maussion C, Moarii M, Pronier E, et al
    Deep learning-based classification of mesothelioma improves prediction of patient outcome.
    Nat Med. 2019;25:1519-1525.
    PubMed     Abstract available


    September 2019
  18. YANG H, Xia L, Chen J, Zhang S, et al
    Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity.
    Nat Med. 2019;25:1428-1441.
    PubMed     Abstract available


    June 2019
  19. ARDILA D, Kiraly AP, Bharadwaj S, Choi B, et al
    Author Correction: End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography.
    Nat Med. 2019 Jun 28. pii: 10.1038/s41591-019-0536.
    PubMed     Abstract available


    May 2019
  20. ARDILA D, Kiraly AP, Bharadwaj S, Choi B, et al
    End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography.
    Nat Med. 2019 May 20. pii: 10.1038/s41591-019-0447.
    PubMed     Abstract available


  21. STOWER H
    Evading the immune system.
    Nat Med. 2019;25:710.
    PubMed    


  22. WANG Z, Yip LY, Lee JHJ, Wu Z, et al
    Methionine is a metabolic dependency of tumor-initiating cells.
    Nat Med. 2019;25:825-837.
    PubMed     Abstract available


  23. RODON J, Soria JC, Berger R, Miller WH, et al
    Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
    Nat Med. 2019;25:751-758.
    PubMed     Abstract available


    March 2019
  24. ABBOTT B
    Spreading the search.
    Nat Med. 2019;25:352-355.
    PubMed    


    January 2019
  25. TEIXEIRA VH, Pipinikas CP, Pennycuick A, Lee-Six H, et al
    Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.
    Nat Med. 2019 Jan 21. pii: 10.1038/s41591-018-0323.
    PubMed     Abstract available


    November 2018
  26. SHAH KN, Bhatt R, Rotow J, Rohrberg J, et al
    Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
    Nat Med. 2018 Nov 26. pii: 10.1038/s41591-018-0264.
    PubMed     Abstract available


  27. FORMENTI SC, Rudqvist NP, Golden E, Cooper B, et al
    Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
    Nat Med. 2018 Nov 5. pii: 10.1038/s41591-018-0232.
    PubMed     Abstract available


    September 2018
  28. COUDRAY N, Ocampo PS, Sakellaropoulos T, Narula N, et al
    Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning.
    Nat Med. 2018 Sep 17. pii: 10.1038/s41591-018-0177.
    PubMed     Abstract available


    August 2018
  29. DERIBE YL, Sun Y, Terranova C, Khan F, et al
    Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
    Nat Med. 2018 Aug 13. pii: 10.1038/s41591-018-0173.
    PubMed     Abstract available


  30. HOYLES L, Fernandez-Real JM, Federici M, Serino M, et al
    Publisher Correction: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
    Nat Med. 2018 Aug 9. pii: 10.1038/s41591-018-0169.
    PubMed     Abstract available


  31. GUO X, Zhang Y, Zheng L, Zheng C, et al
    Publisher Correction: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
    Nat Med. 2018 Aug 9. pii: 10.1038/s41591-018-0167.
    PubMed     Abstract available


  32. GANDARA DR, Paul SM, Kowanetz M, Schleifman E, et al
    Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
    Nat Med. 2018 Aug 6. pii: 10.1038/s41591-018-0134.
    PubMed     Abstract available


    June 2018
  33. GUO X, Zhang Y, Zheng L, Zheng C, et al
    Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.
    Nat Med. 2018 Jun 25. pii: 10.1038/s41591-018-0045.
    PubMed     Abstract available


  34. THOMMEN DS, Koelzer VH, Herzig P, Roller A, et al
    A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
    Nat Med. 2018 Jun 11. pii: 10.1038/s41591-018-0057.
    PubMed     Abstract available


  35. LISSANU DERIBE Y, Sun Y, Terranova C, Khan F, et al
    Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
    Nat Med. 2018 Jun 8. pii: 10.1038/s41591-018-0019.
    PubMed     Abstract available


    May 2018
  36. MAINARDI S, Mulero-Sanchez A, Prahallad A, Germano G, et al
    SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Nat Med. 2018 May 28. pii: 10.1038/s41591-018-0023.
    PubMed     Abstract available


    April 2018
  37. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
    Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Nat Med. 2018 Apr 23. pii: 10.1038/s41591-018-0007.
    PubMed     Abstract available


    March 2018
  38. DARDAEI L, Wang HQ, Singh M, Fordjour P, et al
    SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
    Nat Med. 2018 Mar 5. pii: nm.4497. doi: 10.1038/nm.4497.
    PubMed     Abstract available


    October 2017
  39. ROMERO R, Sayin VI, Davidson SM, Bauer MR, et al
    Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
    Nat Med. 2017 Oct 2. doi: 10.1038/nm.4407.
    PubMed     Abstract available


    August 2017
  40. XUE Y, Martelotto L, Baslan T, Vides A, et al
    An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
    Nat Med. 2017;23:929-937.
    PubMed     Abstract available


    July 2017
  41. MAYORCA-GUILIANI AE, Madsen CD, Cox TR, Horton ER, et al
    ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.
    Nat Med. 2017;23:890-898.
    PubMed     Abstract available


    June 2017
  42. RICKMAN DS, Beltran H, Demichelis F, Rubin MA, et al
    Biology and evolution of poorly differentiated neuroendocrine tumors.
    Nat Med. 2017;23:1-10.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: